SPEAKERS
Li-Tzong Chen
AFFILIATION:
College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
POSITION TITLE:
Chair Professor of Internal Medicine
EDUCATION/TRAINING:
1975.8 - 1982.7 M.D. Kaohsiung Medical College, Kaohsiung, Taiwan
1992.8 – 2001.7 Ph.D. Post-graduate School, Kaohsiung Medical University
HONORS:
2014 Outstanding Clinical Research Award, 24th Wang Ming-Ning Memorial Foundation Award (王民寧基金會: 對醫藥科技發展、國民健康和國家社會傑出貢獻獎), Taipei, Taiwan, December 19th, 2014.
2015 Outstanding Research Award, Ministry of Science and Technology (科技部傑出研究獎), Taipei, Taiwan, May 2nd, 2015.
2015 Outstanding Research Award, Association of Kaohsiung Medical University Alumni (高雄醫學大學傑出校友獎-學術類), Kaohsiung, Taiwan, October 18th, 2015.
2017 Outstanding Biomedical & Biotechnology Award, 12th TienTe Lee Biomedical Foundation (李天德醫藥基金會:卓越醫藥科技獎), Taipei, Taiwan, May 2017.
2018 Outstanding Research Award, Ministry of Science and Technology (科技部傑出研究獎), Taipei, Taiwan, May 28th, 2018.
2018 Gold Medal Award, Technology Transfer Award, 2018 BioTaipei Award (台北生技獎技轉金牌獎), Bio@Taipei, Taipei, Taiwan, July 20, 2018.
2019 6th National Industrial Innovation Award – Innovative Elite Award – Industrial Contribution (Individual Category), Ministry of Economic Affair, ROC. (第六屆經濟部國家產業創新獎 個人類-創新菁英-產學貢獻), Taipei, Taiwan, April 10, 2019.
RESEARCH INTERESTS:
PUBLICATIONS:
1. Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS*, Shan YS*, Chen LT*. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma -TCOG T1211 study. Eur J Cancer 2020 Jan;124:123-130.
2. Macarulla Mercadé T*, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. Pancreas. 2020 Jan;49(1):62-75
3. Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT*. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. Cancer Sci 2020 Feb;111(2):513-527.
4. Chen LT*, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho CF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 2020 Mar;31(3):334-351
5. de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang CH, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DCL, Bogenrieder T, Twelves C and Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer 2020 Apr;122(9):1324-1332
6. AC Roy, J Shapiro, M Burge, C Karapetis, N Pavlakis, E Segelov, I Chau, F Lordick, LT Chen, A Barbour, N Tebutt, T Price. Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy 2020 Apr;20(4):305-324 [2018 IR, 8.676]
7. Shan YS＃, Chen LT＃, Wu JS＃, Chang YF, Lee CT, Wu CH, Chiang NJ, Huang HE, Yen CJ, Chao YJ, Tsai HJ, Chen CY, Kang JW, Kuo CF, Tsai CR, Weng YL, Yang HC, Liu HC, Chang JS. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan. J Biomed Sci 2020 May 26;27(1):69 (# co-first authors)
8. Su YY, Chiang NJ, Tsai HJ, Yen CJ, Shan YS*, Chen LT. The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Report 2020 May;10(1):7420
9. Chen LT*, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 2020 May; 23(3): 510-519
10. Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS*, Shan YS*, Chen LT*. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver Int 2020.05 (online published) doi: 10.1111/liv.14538.
11. Yoo CH, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osda M, Helwig C, Dussault I, Ikeda M*. Phase 1 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in Asian patients with pre-treated biliary tract cancer. J Immunother Cancer 2020 May;8(1):e000564
12. Tsa HJ#, Dai JJ, Chen LT#, Wu MS, Yeh KH, Lin CW, Wang TE, Wang SP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH#, Cheng AL. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Hematologica 2020 Jul;105(7):e349-e354 (#co-first author)